Skip to content

    Ind-Swift Laboratories Q1 FY27 earnings call

    INDSWFTLAB
    Healthcare·17 Aug 2026
    Management Summary

    Ind-Swift Laboratories Limited reported a strong Q1 FY27, with significant growth in operating income and a substantial expansion in EBITDA and PAT margins. The company successfully commercialized key CDMO partnerships and launched new products, driving a meaningful shift towards high-margin export-oriented own-brands. Management expressed confidence in sustaining this growth trajectory and achieving higher margins, while also outlining capital deployment plans for future expansion and R&D.

    Highlights

    5

    • Operating income grew 21.16% year-on-year to ₹186.08 crore from ₹153.58 crore in Q1 FY26.

    • Operating EBITDA improved 2.85x year-on-year to ₹33.32 crore from ₹8.66 crore in the corresponding quarter last year.

    • Operating EBITDA margin expanded sharply by 1258 bps year-on-year to 17.91% from 5.33% in Q1 FY26.

    • PAT (excluding exceptional item) stood at ₹24.68 crore, a 2.04x year-on-year jump from ₹8.12 crore.

    • CDMO partnerships with Viatris, Manx, and Arrotex commercialized, expected to contribute ₹200 to ₹220 crore incremental revenue in FY27.

    Concerns

    2

    • Pace of inorganic growth/partnerships is slow due to 'war' (geopolitical events), delaying announcements.

    • Domestic segments (branded generic, ethical, domestic contract manufacturing) showed slight decline in sales proportion compared to Q1 FY26.

    Key financials

    Single quarter

    05 metrics
    1. 01Operating Income₹186.08 Cr+21.2%YoY
    2. 02Operating EBITDA₹33.32 Cr+2.9%YoY
    3. 03Operating EBITDA Margin17.9%
    4. 04PAT (excl. exceptional)₹24.68 Cr+2.0%YoY
    5. 05PAT Margin13.3%

    Segment breakdown

    Share of Quarterly SalesShare of Quarterly Sales Q1 FY26
    Export - Own Brands57.2%48%
    Export - Contract Manufacturing26.6%29%
    Domestic - Branded Generics6.4%10%
    Domestic - Ethical Division6.1%7%
    Domestic - Contract Manufacturing3.6%6%
    Heatmap· 2 shared metrics

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    ₹250 crores

    Debt

    Debt disclosed

    Liquidity

    Cash ₹250 crores

    Cash on books to be deployed in capex over 2.5 years.

    Guidance & targets

    13
    CategoryTargetPriority
    Revenue
    Incremental revenue from CDMO partnerships (Viatris, Manx, Arrotex)
    ₹200 to ₹220 crore
    		High
    Revenue
    Contribution from Ibuprofen Sachet and Clarithromycin granules (Viatris)
    ₹100-130 crore
    		Medium
    Revenue
    Total contribution from Viatris partnership
    ₹200 crore
    		Medium
    Revenue
    FY30 Revenue
    minimum ₹1500 crore
    		Medium
    Revenue
    Revenue from new CDMO customers (beyond Viatris)
    ₹150 crore
    		Medium
    EBITDA
    Synthimed budgeted EBITDA
    ₹750 crore
    		High
    Margin
    Sustainable EBITDA margins
    18-20%
    		High
    Margin
    EBITDA margins with increased sales
    21-22%
    		Medium
    Net Profit
    FY30 Net Profit
    approx ₹200 crore
    		Medium
    Sales
    Total export sales
    ₹750 crore
    		High
    Sales
    CDMO share of total export sales
    45%
    		High
    Dossiers
    Total dossiers filed
    2500
    		High
    Growth Rate
    CAGR
    20-25%
    		High

    What to watch in Q2 FY27

    5

    EBITDA margin expansion

    after Q2, fully by Q3 FY27
    Current17.91%
    Target20-22%

    Why it matters

    Management expects EBITDA margins to reach 20% after Q2 and 21-22% by Q3, indicating continued profitability improvement.

    Internally, we plan on second quarter, but I don't want to commit so early, but third quarter is what we are fully expecting to increase our EBITDA margins from 18%.

    Risks & concerns

    1
    RiskSeverity

    Slow pace of inorganic growth/partnerships

    Pace of announcing new partnerships for inorganic growth is slow due to geopolitical events ('war'). — Management acknowledged

    low

    Q&A highlights

    8

    “See, the growth story which Mr. Pardeep told, this was for the agreement with Viatris for two products, mainly Ibuprofen and Clarithromycin granules. And we have just kick-started this project, and sales for only these two molecules were hardly 5-6 crores. So, the growth of these molecules will reflect slowly in quarter two and quarter three.”

    Clarified initial revenue contribution from new CDMO deals and phased growth expectation.

    asked by Aryan Bhatia

    2 min read6 chapters

    Detailed Narrative

    01

    Q1 FY27 Financial Performance Overview

    Ind-Swift Laboratories Limited reported a strong Q1 FY27, with operating income growing 21.16% year-on-year to ₹186.08 crore. Operating EBITDA saw a significant increase of 2.85x year-on-year, reaching ₹33.32 crore, and the operating EBITDA margin expanded sharply by 1258 bps to 17.91%. PAT, excluding exceptional items📎, grew 2.04x year-on-year to ₹24.68 crore, with a PAT margin improvement of 827 bps to 13.26%.

    02

    CDMO Partnerships and New Product Launches

    The company successfully commercialized CDMO partnerships with Viatris, Manx (UK), and Arrotex (Australia) during the quarter. These partnerships are projected to contribute an incremental revenue of ₹200 to ₹220 crore in FY27. Specifically, Ibuprofen Sachet and Clarithromycin granules, launched with Viatris, are expected to generate ₹100-130 crore in FY27, with growth anticipated in Q2 and Q3. The total Viatris partnership is expected to contribute ₹200 crore by FY29.

    03

    Product-wise Revenue Mix and Export Focus

    Atorvastatin remained the largest contributor with ₹85.50 crore in FY26, while Ezetimibe + Atorvastatin showed the sharpest growth, more than tripling to ₹80.78 crore in FY26. The export business continues to be the primary growth engine, with own-brands contributing 57.20% of Q1 FY27 sales, up from 48% in Q1 FY26. Export contract manufacturing accounted for 26.64% of Q1 FY27 sales, down slightly from 29% in Q1 FY26, reflecting a strategic shift towards higher-margin own-brands.

    04

    Capacity Expansion & Facility Upgrades

    The company plans to deploy ₹250 crore from its cash reserves over the next 2.5 years for capex. This includes upgrading the Samba manufacturing facility to EU-GMP and PIC/S standards, setting up a new warehouse, and enhancing production capacity for existing molecules. Additionally, the company is establishing a new R&D facility in Panchkula. For potential new CDMO customers, an estimated capex of ₹50-75 crore could generate over ₹150 crore in revenue.

    05

    R&D Capabilities and Product Pipeline

    Ind-Swift Laboratories maintains an R&D facility in Panchkula, focusing on regulatory compliance, tech transfer, and global filings. The R&D team is working on 5-6 new molecules expected to launch between FY27 and FY29, with a focus on therapeutic categories like cardiovascular, anti-diabetic, urology, and gastrointestinal. The company's strategy is to develop molecules only after securing an agreement with customers, with development costs often borne by the customer.

    06

    Margin Outlook and Growth Strategy

    Management expressed confidence in sustaining EBITDA margins of 18-20%, with potential to reach 21-22% if sales increase. The company aims for a 20-25% CAGR in the medium term beyond FY27. For FY30, the target is a minimum revenue of ₹1500 crore and a net profit of approximately ₹200 crore. Total export sales for FY27 are projected at ₹750 crore, with 45% expected from the CDMO business. The company also targets increasing its total dossiers filed from 2100+ to 2500 by Q4 FY27.

    This is an AI-generated summary of a publicly available earnings call transcript.